Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 161

1.

Cytomegalovirus infection is a risk factor for TB disease in Infants.

Müller J, Tanner R, Matsumiya M, Snowden MA, Landry B, Satti I, Harris SA, O'Shea MK, Stockdale L, Marsay L, Chomka A, Harrington-Kandt R, Manjaly Thomas ZR, Stylianou E, Naranbhai V, Mbandi SK, Hatherill M, Hussey G, Mahomed H, Tameris M, McClain JB, Hanekom WA, Evans TG, Scriba TJ, McShane H, Fletcher HA.

JCI Insight. 2019 Nov 7. pii: 130090. doi: 10.1172/jci.insight.130090. [Epub ahead of print]

2.

Tuberculosis Vaccine Development: Progress in Clinical Evaluation.

Sable SB, Posey JE, Scriba TJ.

Clin Microbiol Rev. 2019 Oct 30;33(1). pii: e00100-19. doi: 10.1128/CMR.00100-19. Print 2019 Dec 18. Review.

PMID:
31666281
3.

Final Analysis of a Trial of M72/AS01E Vaccine to Prevent Tuberculosis.

Tait DR, Hatherill M, Van Der Meeren O, Ginsberg AM, Van Brakel E, Salaun B, Scriba TJ, Akite EJ, Ayles HM, Bollaerts A, Demoitié MA, Diacon A, Evans TG, Gillard P, Hellström E, Innes JC, Lempicki M, Malahleha M, Martinson N, Mesia Vela D, Muyoyeta M, Nduba V, Pascal TG, Tameris M, Thienemann F, Wilkinson RJ, Roman F.

N Engl J Med. 2019 Oct 29. doi: 10.1056/NEJMoa1909953. [Epub ahead of print]

PMID:
31661198
4.

MR1-Independent Activation of Human Mucosal-Associated Invariant T Cells by Mycobacteria.

Suliman S, Murphy M, Musvosvi M, Gela A, Meermeier EW, Geldenhuys H, Hopley C, Toefy A, Bilek N, Veldsman A, Hanekom WA, Johnson JL, Boom WH, Obermoser G, Huang H, Hatherill M, Lewinsohn DM, Nemes E, Scriba TJ.

J Immunol. 2019 Oct 14. pii: ji1900674. doi: 10.4049/jimmunol.1900674. [Epub ahead of print]

PMID:
31611259
5.

Plasma Type I IFN Protein Concentrations in Human Tuberculosis.

Llibre A, Bilek N, Bondet V, Darboe F, Mbandi SK, Penn-Nicholson A, Hatherill M, Rozenberg F, Scriba TJ, Duffy D.

Front Cell Infect Microbiol. 2019 Aug 22;9:296. doi: 10.3389/fcimb.2019.00296. eCollection 2019.

6.

Live-attenuated Mycobacterium tuberculosis vaccine MTBVAC versus BCG in adults and neonates: a randomised controlled, double-blind dose-escalation trial.

Tameris M, Mearns H, Penn-Nicholson A, Gregg Y, Bilek N, Mabwe S, Geldenhuys H, Shenje J, Luabeya AKK, Murillo I, Doce J, Aguilo N, Marinova D, Puentes E, Rodríguez E, Gonzalo-Asensio J, Fritzell B, Thole J, Martin C, Scriba TJ, Hatherill M; MTBVAC Clinical Trial Team.

Lancet Respir Med. 2019 Sep;7(9):757-770. doi: 10.1016/S2213-2600(19)30251-6. Epub 2019 Aug 12.

PMID:
31416768
7.

Potential population level impact on tuberculosis incidence of using an mRNA expression signature correlate-of-risk test to target tuberculosis preventive therapy.

Sumner T, Scriba TJ, Penn-Nicholson A, Hatherill M, White RG.

Sci Rep. 2019 Jul 31;9(1):11126. doi: 10.1038/s41598-019-47645-z.

8.

Correction: Discovery and validation of a prognostic proteomic signature for tuberculosis progression: A prospective cohort study.

Penn-Nicholson A, Hraha T, Thompson EG, Sterling D, Mbandi SK, Wall KM, Fisher M, Suliman S, Shankar S, Hanekom WA, Janjic N, Hatherill M, Kaufmann SHE, Sutherland J, Walzl G, De Groote MA, Ochsner U, Zak DE, Scriba TJ; ACS and GC6–74 cohort study groups.

PLoS Med. 2019 Jul 18;16(7):e1002880. doi: 10.1371/journal.pmed.1002880. eCollection 2019 Jul.

9.

Multinomial modelling of TB/HIV co-infection yields a robust predictive signature and generates hypotheses about the HIV+TB+ disease state.

Duffy FJ, Thompson EG, Scriba TJ, Zak DE.

PLoS One. 2019 Jul 15;14(7):e0219322. doi: 10.1371/journal.pone.0219322. eCollection 2019.

10.

Detection of Tuberculosis Recurrence, Diagnosis and Treatment Response by a Blood Transcriptomic Risk Signature in HIV-Infected Persons on Antiretroviral Therapy.

Darboe F, Mbandi SK, Naidoo K, Yende-Zuma N, Lewis L, Thompson EG, Duffy FJ, Fisher M, Filander E, van Rooyen M, Bilek N, Mabwe S, McKinnon LR, Chegou N, Loxton A, Walzl G, Tromp G, Padayatchi N, Govender D, Hatherill M, Karim SA, Zak DE, Penn-Nicholson A, Scriba TJ; SATVI Clinical Immunology Team.

Front Microbiol. 2019 Jun 26;10:1441. doi: 10.3389/fmicb.2019.01441. eCollection 2019.

11.

Moving tuberculosis vaccines from theory to practice.

Andersen P, Scriba TJ.

Nat Rev Immunol. 2019 Sep;19(9):550-562. doi: 10.1038/s41577-019-0174-z. Review.

PMID:
31114037
12.

Select sequencing of clonally expanded CD8+ T cells reveals limits to clonal expansion.

Huang H, Sikora MJ, Islam S, Chowdhury RR, Chien YH, Scriba TJ, Davis MM, Steinmetz LM.

Proc Natl Acad Sci U S A. 2019 Apr 30;116(18):8995-9001. doi: 10.1073/pnas.1902649116. Epub 2019 Apr 16.

13.

Discovery and validation of a prognostic proteomic signature for tuberculosis progression: A prospective cohort study.

Penn-Nicholson A, Hraha T, Thompson EG, Sterling D, Mbandi SK, Wall KM, Fisher M, Suliman S, Shankar S, Hanekom WA, Janjic N, Hatherill M, Kaufmann SHE, Sutherland J, Walzl G, De Groote MA, Ochsner U, Zak DE, Scriba TJ; ACS and GC6–74 cohort study groups.

PLoS Med. 2019 Apr 16;16(4):e1002781. doi: 10.1371/journal.pmed.1002781. eCollection 2019 Apr. Erratum in: PLoS Med. 2019 Jul 18;16(7):e1002880.

14.

Immunometabolic Signatures Predict Risk of Progression to Active Tuberculosis and Disease Outcome.

Duffy FJ, Weiner J 3rd, Hansen S, Tabb DL, Suliman S, Thompson E, Maertzdorf J, Shankar S, Tromp G, Parida S, Dover D, Axthelm MK, Sutherland JS, Dockrell HM, Ottenhoff THM, Scriba TJ, Picker LJ, Walzl G, Kaufmann SHE, Zak DE; GC6-74 Consortium.

Front Immunol. 2019 Mar 22;10:527. doi: 10.3389/fimmu.2019.00527. eCollection 2019.

15.

A comparison of antigen-specific T cell responses induced by six novel tuberculosis vaccine candidates.

Rodo MJ, Rozot V, Nemes E, Dintwe O, Hatherill M, Little F, Scriba TJ.

PLoS Pathog. 2019 Mar 4;15(3):e1007643. doi: 10.1371/journal.ppat.1007643. eCollection 2019 Mar.

16.

Protection against tuberculosis by mucosal BCG administration.

Scriba TJ, Nemes E.

Nat Med. 2019 Feb;25(2):199-201. doi: 10.1038/s41591-019-0347-0. No abstract available.

PMID:
30692698
17.

Diagnostic Accuracy of Early Secretory Antigenic Target-6-Free Interferon-gamma Release Assay Compared to QuantiFERON-TB Gold In-tube.

Nemes E, Abrahams D, Scriba TJ, Ratangee F, Keyser A, Makhethe L, Erasmus M, Mabwe S, Bilek N, Rozot V, Geldenhuys H, Hatherill M, Lempicki MD, Holm LL, Bogardus L, Ginsberg AM, Blauenfeldt T, Smith B, Ellis RD, Loxton AG, Walzl G, Andersen P, Ruhwald M.

Clin Infect Dis. 2019 Oct 30;69(10):1724-1730. doi: 10.1093/cid/ciz034.

18.

The effect of antiretroviral treatment on selected genes in whole blood from HIV-infected adults sensitised by Mycobacterium tuberculosis.

Jhilmeet N, Lowe DM, Riou C, Scriba TJ, Coussens A, Goliath R, Wilkinson RJ, Wilkinson KA.

PLoS One. 2018 Dec 27;13(12):e0209516. doi: 10.1371/journal.pone.0209516. eCollection 2018.

19.

Toll-like receptor chaperone HSP90B1 and the immune response to Mycobacteria.

Graustein AD, Misch EA, Musvosvi M, Shey M, Shah JA, Seshadri C, Aguoju A, Bowman K, Mulenga H, Veldsman A, Hanekom WA, Hatherill M, Scriba TJ, Hawn TR.

PLoS One. 2018 Dec 14;13(12):e0208940. doi: 10.1371/journal.pone.0208940. eCollection 2018.

20.

Batf2 differentially regulates tissue immunopathology in Type 1 and Type 2 diseases.

Guler R, Mpotje T, Ozturk M, Nono JK, Parihar SP, Chia JE, Abdel Aziz N, Hlaka L, Kumar S, Roy S, Penn-Nicholson A, Hanekom WA, Zak DE, Scriba TJ, Suzuki H, Brombacher F.

Mucosal Immunol. 2019 Mar;12(2):390-402. doi: 10.1038/s41385-018-0108-2. Epub 2018 Dec 12.

PMID:
30542107
21.

Metabolite changes in blood predict the onset of tuberculosis.

Weiner J 3rd, Maertzdorf J, Sutherland JS, Duffy FJ, Thompson E, Suliman S, McEwen G, Thiel B, Parida SK, Zyla J, Hanekom WA, Mohney RP, Boom WH, Mayanja-Kizza H, Howe R, Dockrell HM, Ottenhoff THM, Scriba TJ, Zak DE, Walzl G, Kaufmann SHE; GC6-74 consortium.

Nat Commun. 2018 Dec 6;9(1):5208. doi: 10.1038/s41467-018-07635-7.

22.

Author Correction: A multi-cohort study of the immune factors associated with M. tuberculosis infection outcomes.

Roy Chowdhury R, Vallania F, Yang Q, Lopez Angel CJ, Darboe F, Penn-Nicholson A, Rozot V, Nemes E, Malherbe ST, Ronacher K, Walzl G, Hanekom W, Davis MM, Winter J, Chen X, Scriba TJ, Khatri P, Chien YH.

Nature. 2018 Dec;564(7734):E5. doi: 10.1038/s41586-018-0635-8.

23.

Can we predict tuberculosis cure? What tools are available?

Goletti D, Lindestam Arlehamn CS, Scriba TJ, Anthony R, Cirillo DM, Alonzi T, Denkinger CM, Cobelens F.

Eur Respir J. 2018 Nov 8;52(5). pii: 1801089. doi: 10.1183/13993003.01089-2018. Print 2018 Nov. Review.

24.

Phase 2b Controlled Trial of M72/AS01E Vaccine to Prevent Tuberculosis.

Van Der Meeren O, Hatherill M, Nduba V, Wilkinson RJ, Muyoyeta M, Van Brakel E, Ayles HM, Henostroza G, Thienemann F, Scriba TJ, Diacon A, Blatner GL, Demoitié MA, Tameris M, Malahleha M, Innes JC, Hellström E, Martinson N, Singh T, Akite EJ, Khatoon Azam A, Bollaerts A, Ginsberg AM, Evans TG, Gillard P, Tait DR.

N Engl J Med. 2018 Oct 25;379(17):1621-1634. doi: 10.1056/NEJMoa1803484. Epub 2018 Sep 25.

25.

Using vaccine Immunostimulation/Immunodynamic modelling methods to inform vaccine dose decision-making.

Rhodes SJ, Guedj J, Fletcher HA, Lindenstrøm T, Scriba TJ, Evans TG, Knight GM, White RG.

NPJ Vaccines. 2018 Sep 17;3:36. doi: 10.1038/s41541-018-0075-3. eCollection 2018.

26.

Allelic resolution NGS HLA typing of Class I and Class II loci and haplotypes in Cape Town, South Africa.

Thorstenson YR, Creary LE, Huang H, Rozot V, Nguyen TT, Babrzadeh F, Kancharla S, Fukushima M, Kuehn R, Wang C, Li M, Krishnakumar S, Mindrinos M, Fernandez Viña MA, Scriba TJ, Davis MM.

Hum Immunol. 2018 Dec;79(12):839-847. doi: 10.1016/j.humimm.2018.09.004. Epub 2018 Sep 18.

PMID:
30240896
27.

Integrating Non-human Primate, Human, and Mathematical Studies to Determine the Influence of BCG Timing on H56 Vaccine Outcomes.

Joslyn LR, Pienaar E, DiFazio RM, Suliman S, Kagina BM, Flynn JL, Scriba TJ, Linderman JJ, Kirschner DE.

Front Microbiol. 2018 Aug 17;9:1734. doi: 10.3389/fmicb.2018.01734. eCollection 2018.

28.

Differential DNA methylation of potassium channel KCa3.1 and immune signalling pathways is associated with infant immune responses following BCG vaccination.

Hasso-Agopsowicz M, Scriba TJ, Hanekom WA, Dockrell HM, Smith SG.

Sci Rep. 2018 Aug 30;8(1):13086. doi: 10.1038/s41598-018-31537-9.

29.

A multi-cohort study of the immune factors associated with M. tuberculosis infection outcomes.

Roy Chowdhury R, Vallania F, Yang Q, Lopez Angel CJ, Darboe F, Penn-Nicholson A, Rozot V, Nemes E, Malherbe ST, Ronacher K, Walzl G, Hanekom W, Davis MM, Winter J, Chen X, Scriba TJ, Khatri P, Chien YH.

Nature. 2018 Aug;560(7720):644-648. doi: 10.1038/s41586-018-0439-x. Epub 2018 Aug 22. Erratum in: Nature. 2018 Dec;564(7734):E5.

30.

Dose Optimization of H56:IC31 Vaccine for Tuberculosis-Endemic Populations. A Double-Blind, Placebo-controlled, Dose-Selection Trial.

Suliman S, Luabeya AKK, Geldenhuys H, Tameris M, Hoff ST, Shi Z, Tait D, Kromann I, Ruhwald M, Rutkowski KT, Shepherd B, Hokey D, Ginsberg AM, Hanekom WA, Andersen P, Scriba TJ, Hatherill M; H56-035 Trial Group.

Am J Respir Crit Care Med. 2019 Jan 15;199(2):220-231. doi: 10.1164/rccm.201802-0366OC.

PMID:
30092143
31.

Prospects for a vaccine to prevent HIV-related tuberculosis.

Nemes E, Scriba TJ, Hatherill M.

Curr Opin HIV AIDS. 2018 Nov;13(6):522-527. doi: 10.1097/COH.0000000000000496. Review.

PMID:
30080682
32.

Diagnostic Challenge of Tuberculosis Heterogeneity.

Nemes E, Meermeier EW, Scriba TJ, Walzl G, Malherbe ST, Lewinsohn DM.

Semin Respir Crit Care Med. 2018 Jun;39(3):286-296. doi: 10.1055/s-0038-1660471. Epub 2018 Aug 2. Review.

PMID:
30071544
33.

Elevated IgG Responses in Infants Are Associated With Reduced Prevalence of Mycobacterium tuberculosis Infection.

Logan E, Luabeya AKK, Mulenga H, Mrdjen D, Ontong C, Cunningham AF, Tameris M, McShane H, Scriba TJ, Horsnell WGC, Hatherill M.

Front Immunol. 2018 Jul 2;9:1529. doi: 10.3389/fimmu.2018.01529. eCollection 2018.

34.

Prevention of M. tuberculosis Infection with H4:IC31 Vaccine or BCG Revaccination.

Nemes E, Geldenhuys H, Rozot V, Rutkowski KT, Ratangee F, Bilek N, Mabwe S, Makhethe L, Erasmus M, Toefy A, Mulenga H, Hanekom WA, Self SG, Bekker LG, Ryall R, Gurunathan S, DiazGranados CA, Andersen P, Kromann I, Evans T, Ellis RD, Landry B, Hokey DA, Hopkins R, Ginsberg AM, Scriba TJ, Hatherill M; C-040-404 Study Team.

N Engl J Med. 2018 Jul 12;379(2):138-149. doi: 10.1056/NEJMoa1714021.

35.

A Diverse Lipid Antigen-Specific TCR Repertoire Is Clonally Expanded during Active Tuberculosis.

DeWitt WS, Yu KKQ, Wilburn DB, Sherwood A, Vignali M, Day CL, Scriba TJ, Robins HS, Swanson WJ, Emerson RO, Bradley PH, Seshadri C.

J Immunol. 2018 Aug 1;201(3):888-896. doi: 10.4049/jimmunol.1800186. Epub 2018 Jun 18.

36.

A Serum Circulating miRNA Signature for Short-Term Risk of Progression to Active Tuberculosis Among Household Contacts.

Duffy FJ, Thompson E, Downing K, Suliman S, Mayanja-Kizza H, Boom WH, Thiel B, Weiner Iii J, Kaufmann SHE, Dover D, Tabb DL, Dockrell HM, Ottenhoff THM, Tromp G, Scriba TJ, Zak DE, Walzl G; GC6-74 Consortium.

Front Immunol. 2018 Apr 13;9:661. doi: 10.3389/fimmu.2018.00661. eCollection 2018.

37.

Validation of a CD1b tetramer assay for studies of human mycobacterial infection or vaccination.

Layton ED, Yu KKQ, Smith MT, Scriba TJ, De Rosa SC, Seshadri C.

J Immunol Methods. 2018 Jul;458:44-52. doi: 10.1016/j.jim.2018.04.004. Epub 2018 Apr 21.

38.

Four-gene Pan-African Blood Signature Predicts Progression to Tuberculosis.

Suliman S, Thompson E, Sutherland J, Weiner Rd J, Ota MOC, Shankar S, Penn-Nicholson A, Thiel B, Erasmus M, Maertzdorf J, Duffy FJ, Hill PC, Hughes EJ, Stanley K, Downing K, Fisher ML, Valvo J, Parida SK, van der Spuy G, Tromp G, Adetifa IMO, Donkor S, Howe R, Mayanja-Kizza H, Boom WH, Dockrell H, Ottenhoff THM, Hatherill M, Aderem A, Hanekom WA, Scriba TJ, Kaufmann SH, Zak DE, Walzl G; GC6-74 and ACS cohort study groups.

Am J Respir Crit Care Med. 2018 Apr 6. doi: 10.1164/rccm.201711-2340OC. [Epub ahead of print]

39.

Safety and immunogenicity of the novel tuberculosis vaccine ID93 + GLA-SE in BCG-vaccinated healthy adults in South Africa: a randomised, double-blind, placebo-controlled phase 1 trial.

Penn-Nicholson A, Tameris M, Smit E, Day TA, Musvosvi M, Jayashankar L, Vergara J, Mabwe S, Bilek N, Geldenhuys H, Luabeya AK, Ellis R, Ginsberg AM, Hanekom WA, Reed SG, Coler RN, Scriba TJ, Hatherill M; TBVPX-114 study team.

Lancet Respir Med. 2018 Apr;6(4):287-298. doi: 10.1016/S2213-2600(18)30077-8.

PMID:
29595510
40.

T-cell biomarkers for diagnosis of tuberculosis: candidate evaluation by a simple whole blood assay for clinical translation.

Musvosvi M, Duffy D, Filander E, Africa H, Mabwe S, Jaxa L, Bilek N, Llibre A, Rouilly V, Hatherill M, Albert M, Scriba TJ, Nemes E.

Eur Respir J. 2018 Mar 22;51(3). pii: 1800153. doi: 10.1183/13993003.00153-2018. Print 2018 Mar. No abstract available.

41.

Considerations for biomarker-targeted intervention strategies for tuberculosis disease prevention.

Fiore-Gartland A, Carpp LN, Naidoo K, Thompson E, Zak DE, Self S, Churchyard G, Walzl G, Penn-Nicholson A, Scriba TJ, Hatherill M.

Tuberculosis (Edinb). 2018 Mar;109:61-68. doi: 10.1016/j.tube.2017.11.009. Epub 2017 Nov 22.

42.

Functional, Antigen-Specific Stem Cell Memory (TSCM) CD4+ T Cells Are Induced by Human Mycobacterium tuberculosis Infection.

Mpande CAM, Dintwe OB, Musvosvi M, Mabwe S, Bilek N, Hatherill M, Nemes E, Scriba TJ; SATVI Clinical Immunology Team.

Front Immunol. 2018 Mar 1;9:324. doi: 10.3389/fimmu.2018.00324. eCollection 2018.

43.

Diagnostic performance of an optimized transcriptomic signature of risk of tuberculosis in cryopreserved peripheral blood mononuclear cells.

Darboe F, Mbandi SK, Thompson EG, Fisher M, Rodo M, van Rooyen M, Filander E, Bilek N, Mabwe S, Hatherill M, Zak DE, Penn-Nicholson A, Scriba TJ; SATVI Clinical Immunology Team.

Tuberculosis (Edinb). 2018 Jan;108:124-126. doi: 10.1016/j.tube.2017.11.001. Epub 2017 Nov 6. No abstract available.

PMID:
29523312
44.

CD1b Tetramers Identify T Cells that Recognize Natural and Synthetic Diacylated Sulfoglycolipids from Mycobacterium tuberculosis.

James CA, Yu KKQ, Gilleron M, Prandi J, Yedulla VR, Moleda ZZ, Diamanti E, Khan M, Aggarwal VK, Reijneveld JF, Reinink P, Lenz S, Emerson RO, Scriba TJ, Souter MNT, Godfrey DI, Pellicci DG, Moody DB, Minnaard AJ, Seshadri C, Van Rhijn I.

Cell Chem Biol. 2018 Apr 19;25(4):392-402.e14. doi: 10.1016/j.chembiol.2018.01.006. Epub 2018 Feb 1.

45.

Sequence-based HLA-A, B, C, DP, DQ, and DR typing of 159 individuals from the Worcester region of the Western Cape province of South Africa.

Grifoni A, Sidney J, Carpenter C, Phillips E, Mallal S, Scriba TJ, Sette A, Lindestam Arlehamn CS.

Hum Immunol. 2018 Mar;79(3):143-144. doi: 10.1016/j.humimm.2018.01.004.

PMID:
29398200
46.

Protein kinase C-delta (PKCδ), a marker of inflammation and tuberculosis disease progression in humans, is important for optimal macrophage killing effector functions and survival in mice.

Parihar SP, Ozturk M, Marakalala MJ, Loots DT, Hurdayal R, Beukes D, Van Reenen M, Zak DE, Mbandi SK, Darboe F, Penn-Nicholson A, Hanekom WA, Leitges M, Scriba TJ, Guler R, Brombacher F.

Mucosal Immunol. 2018 Mar;11(2):579-580. doi: 10.1038/mi.2017.108. Epub 2017 Dec 20.

PMID:
29346346
47.

Comparison of CyTOF assays across sites: Results of a six-center pilot study.

Leipold MD, Obermoser G, Fenwick C, Kleinstuber K, Rashidi N, McNevin JP, Nau AN, Wagar LE, Rozot V, Davis MM, DeRosa S, Pantaleo G, Scriba TJ, Walker BD, Olsen LR, Maecker HT.

J Immunol Methods. 2018 Feb;453:37-43. doi: 10.1016/j.jim.2017.11.008. Epub 2017 Nov 23.

48.

Sequential inflammatory processes define human progression from M. tuberculosis infection to tuberculosis disease.

Scriba TJ, Penn-Nicholson A, Shankar S, Hraha T, Thompson EG, Sterling D, Nemes E, Darboe F, Suliman S, Amon LM, Mahomed H, Erasmus M, Whatney W, Johnson JL, Boom WH, Hatherill M, Valvo J, De Groote MA, Ochsner UA, Aderem A, Hanekom WA, Zak DE; other members of the ACS cohort study team.

PLoS Pathog. 2017 Nov 16;13(11):e1006687. doi: 10.1371/journal.ppat.1006687. eCollection 2017 Nov.

49.

Comparison of haematology and biochemistry parameters in healthy South African infants with laboratory reference intervals.

Schmidt BM, Tameris M, Geldenhuys H, Luabeya A, Bunyasi E, Hawkridge T, McClain JB, Mahomed H, Scriba TJ, McShane H, Hatherill M.

Trop Med Int Health. 2018 Jan;23(1):63-68. doi: 10.1111/tmi.13009. Epub 2017 Dec 4.

50.

Polyfunctional CD4+ T Cells As Targets for Tuberculosis Vaccination.

Lewinsohn DA, Lewinsohn DM, Scriba TJ.

Front Immunol. 2017 Oct 5;8:1262. doi: 10.3389/fimmu.2017.01262. eCollection 2017. Review.

Supplemental Content

Loading ...
Support Center